A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3K alpha Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies

Trial Profile

A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3K alpha Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Sapanisertib (Primary) ; TAK 117 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 02 Dec 2016 Results assessing safety, pharmacokinetics, pharmacodynamics and preliminary activity of TAK-228 + TAK-117 (n=77) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top